Karl Tronstad: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(added conf talk) |
Notjusttired (talk | contribs) m (→Notable ME/CFS studies: add) |
||
| Line 2: | Line 2: | ||
'''Karl Johan Tronstad''', PhD, is a professor in the Department of Biomedicine, University of Bergen, Bergen, Norway, where he heads the Tronstad Lab which studies cell metabolism and mitochondrial involvement in cancer and [[Myalgic Encephalomyelitis]]/[[Chronic Fatigue Syndrome]] ([[ME/CFS]]). In 2017, his research group received a grant of 9.5 million for the development of new [[ME/CFS]] treatment methods and biomarkers. Dr. Tronstad collaborates with Professor [[Olav Mella]] and [[Øystein Fluge]] at the Department of Oncology and Medical Physics at Haukeland University Hospital on [[ME/CFS]] research.<ref>http://www.uib.no/en/biomedisin/108972/finding-cause-chronic-fatigue-syndromeme</ref> | '''Karl Johan Tronstad''', PhD, is a professor in the Department of Biomedicine, University of Bergen, Bergen, Norway, where he heads the Tronstad Lab which studies cell metabolism and mitochondrial involvement in cancer and [[Myalgic Encephalomyelitis]]/[[Chronic Fatigue Syndrome]] ([[ME/CFS]]). In 2017, his research group received a grant of 9.5 million for the development of new [[ME/CFS]] treatment methods and biomarkers. Dr. Tronstad collaborates with Professor [[Olav Mella]] and [[Øystein Fluge]] at the Department of Oncology and Medical Physics at Haukeland University Hospital on [[ME/CFS]] research.<ref>http://www.uib.no/en/biomedisin/108972/finding-cause-chronic-fatigue-syndromeme</ref> | ||
==Notable | ==Notable studies== | ||
*2016, Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome<ref name="Fluge, 2016" /> [https://insight.jci.org/articles/view/89376 (Full Text)] | *2016, Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome<ref name="Fluge, 2016" /> [https://insight.jci.org/articles/view/89376 (Full Text)] | ||
* 2020, Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study<ref name="Rekeland2020">{{Cite journal|last=Rekeland|first=Ingrid G.|author-link=|last2=Fosså|first2=Alexander|author-link2=|last3=Lande|first3=Asgeir|author-link3=|last4=Ktoridou-Valen|first4=Irini|author-link4=|last5=Sørland|first5=Kari|author-link5=|last6=Holsen|first6=Mari|author-link6=|last7=Tronstad|first7=Karl J.|author-link7=Karl Tronstad|last8=Risa|first8=Kristin|author-link8=|last9=Alme|first9=Kine|author-link9=|date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Frontiers in Medicine|language=English|volume=7|issue=162|pages=|doi=10.3389/fmed.2020.00162|issn=2296-858X|pmc=|pmid=|access-date=|quote=|via=|last10=Viken|first10=Marte K.|author-link10=|last11=Lie|first11=Benedicte K.|author-link11=|last12=Dahl|first12=Olav|author-link12=|last13=Mella|first13=Olav|author-link13=Olav Mella|first14=Øystein|last14=Fluge|author-link14=Øystein Fluge}}</ref> - [https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full? (Full text)] | |||
==Talks and interviews== | ==Talks and interviews== | ||
Revision as of 01:40, May 6, 2020
Karl Johan Tronstad, PhD, is a professor in the Department of Biomedicine, University of Bergen, Bergen, Norway, where he heads the Tronstad Lab which studies cell metabolism and mitochondrial involvement in cancer and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). In 2017, his research group received a grant of 9.5 million for the development of new ME/CFS treatment methods and biomarkers. Dr. Tronstad collaborates with Professor Olav Mella and Øystein Fluge at the Department of Oncology and Medical Physics at Haukeland University Hospital on ME/CFS research.[1]
Notable studies[edit | edit source]
- 2016, Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome[2] (Full Text)
- 2020, Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study[3] - (Full text)
Talks and interviews[edit | edit source]
- 2019, Speaker at the 14th Invest in ME International ME Conference; Speech title: Metabolic profiling and associations to clinical data in ME - (Video)
Online presence[edit | edit source]
Learn more[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
- ↑ http://www.uib.no/en/biomedisin/108972/finding-cause-chronic-fatigue-syndromeme
- ↑ Fluge, Øystein; Mella, Olav; Bruland, Ove; Risa, Kristin; Dyrstad, Sissel E.; Alme, Kine; Rekeland, Ingrid G.; Sapkota, Dipak; Røsland, Gro V.; Fosså, Alexander; Ktoridou-Valen, Irini; Lunde, Sigrid; Sørland, Kari; Lien, Katarina; Herder, Ingrid; Thürmer, Hanne; Gotaas, Merete E.; Baranowska, Katarzyna A.; Bohnen, Louis M.L.J.; Schäfer, Christoph; McCann, Adrian; Sommerfelt, Kristian; Helgeland, Lars; Ueland, Per M.; Dahl, Olav; Tronstad, Karl J. (2016), "Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome", JCI Insight, 1 (21), doi:10.1172/jci.insight.89376
- ↑ Rekeland, Ingrid G.; Fosså, Alexander; Lande, Asgeir; Ktoridou-Valen, Irini; Sørland, Kari; Holsen, Mari; Tronstad, Karl J.; Risa, Kristin; Alme, Kine; Viken, Marte K.; Lie, Benedicte K.; Dahl, Olav; Mella, Olav; Fluge, Øystein (2020). "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study". Frontiers in Medicine. 7 (162). doi:10.3389/fmed.2020.00162. ISSN 2296-858X.
